Premium
The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs)
Author(s) -
Wang Lucia,
Sharma Abhishek
Publication year - 2020
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000473
Subject(s) - fulvestrant , estrogen receptor , pharmacology , chemistry , estrogen , estrogen receptor alpha , bioavailability , selective estrogen receptor modulator , breast cancer , cancer research , medicine , cancer
Estrogen receptor‐alpha (ERα) is the target of endocrine therapies for the treatment of more than 70 % of ERα‐positive breast cancers. Selective estrogen receptor degraders (SERDs) antagonize estrogen binding and target the receptor for degradation, representing the last line of treatment for resistant metastatic breast cancer patients. However, the clinical efficacy of the lone clinically approved SERD (Fulvestrant) is limited by its poor oral bioavailability. Recently, several analogues of GW5638, an acrylic acid‐based ERα ligand developed by Glaxo Research Institute in 1994, have been reported as promising orally bioavailable SERDs. Some of these compounds are currently in clinical trials, while various other structurally novel SERDs have also been reported by pharma as well as academic research groups. This review provides a critical analysis of the recent developments in orally available SERDs, with a focus on the structure–activity relationships, binding interactions and pharmacokinetic properties of these compounds